Eric Wu
Concepts (357)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Care Costs | 28 | 2022 | 395 | 3.930 |
Why?
| Everolimus | 10 | 2016 | 68 | 2.530 |
Why?
| Health Resources | 8 | 2022 | 120 | 2.380 |
Why?
| Cost of Illness | 12 | 2022 | 288 | 2.120 |
Why?
| Receptor, ErbB-2 | 9 | 2016 | 336 | 1.540 |
Why?
| Breast Neoplasms | 12 | 2016 | 2139 | 1.420 |
Why?
| Hyperkalemia | 2 | 2020 | 26 | 1.250 |
Why?
| Medication Adherence | 6 | 2016 | 573 | 1.230 |
Why?
| Receptors, Estrogen | 3 | 2015 | 428 | 1.200 |
Why?
| Receptors, Antigen, T-Cell | 4 | 2021 | 701 | 1.170 |
Why?
| Immunotherapy, Adoptive | 2 | 2020 | 295 | 1.090 |
Why?
| Health Expenditures | 6 | 2020 | 184 | 1.050 |
Why?
| Practice Patterns, Physicians' | 4 | 2016 | 1266 | 1.020 |
Why?
| Health Services | 6 | 2016 | 103 | 0.970 |
Why?
| United States | 39 | 2022 | 13876 | 0.870 |
Why?
| Receptors, Progesterone | 2 | 2015 | 345 | 0.850 |
Why?
| Models, Economic | 2 | 2020 | 55 | 0.840 |
Why?
| Hepatitis C, Chronic | 2 | 2015 | 153 | 0.840 |
Why?
| Antifungal Agents | 4 | 2017 | 125 | 0.800 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 113 | 0.780 |
Why?
| Middle Aged | 52 | 2020 | 30893 | 0.750 |
Why?
| Antineoplastic Agents | 9 | 2016 | 2058 | 0.750 |
Why?
| Hospital Costs | 3 | 2020 | 116 | 0.720 |
Why?
| Gout | 2 | 2012 | 36 | 0.710 |
Why?
| Retrospective Studies | 31 | 2022 | 14460 | 0.700 |
Why?
| Aged | 38 | 2022 | 21971 | 0.700 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 280 | 0.680 |
Why?
| Nocturia | 1 | 2019 | 8 | 0.670 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2016 | 1565 | 0.670 |
Why?
| Kaplan-Meier Estimate | 10 | 2017 | 857 | 0.620 |
Why?
| Proportional Hazards Models | 12 | 2017 | 1208 | 0.620 |
Why?
| Female | 63 | 2021 | 68127 | 0.610 |
Why?
| Cost-Benefit Analysis | 12 | 2022 | 581 | 0.610 |
Why?
| Hospitalization | 13 | 2021 | 2071 | 0.610 |
Why?
| Depressive Disorder, Major | 3 | 2011 | 347 | 0.590 |
Why?
| Candida | 2 | 2017 | 35 | 0.580 |
Why?
| Nutrition Surveys | 1 | 2019 | 262 | 0.580 |
Why?
| Proline | 2 | 2015 | 78 | 0.580 |
Why?
| Fluconazole | 1 | 2017 | 18 | 0.560 |
Why?
| Candidemia | 1 | 2017 | 9 | 0.560 |
Why?
| Humans | 80 | 2022 | 128524 | 0.560 |
Why?
| Myocardial Perfusion Imaging | 1 | 2017 | 36 | 0.550 |
Why?
| Male | 53 | 2021 | 62883 | 0.550 |
Why?
| Medicare | 7 | 2022 | 718 | 0.540 |
Why?
| Cardiologists | 1 | 2017 | 46 | 0.540 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 78 | 0.540 |
Why?
| Fees, Pharmaceutical | 3 | 2016 | 13 | 0.540 |
Why?
| Prevalence | 10 | 2020 | 2549 | 0.530 |
Why?
| Oligopeptides | 2 | 2015 | 257 | 0.530 |
Why?
| Adult | 41 | 2022 | 35315 | 0.520 |
Why?
| Thrombolytic Therapy | 1 | 2017 | 132 | 0.520 |
Why?
| Insurance Claim Review | 8 | 2017 | 72 | 0.510 |
Why?
| Biological Therapy | 1 | 2016 | 29 | 0.510 |
Why?
| Antirheumatic Agents | 2 | 2016 | 282 | 0.510 |
Why?
| Citalopram | 3 | 2011 | 34 | 0.500 |
Why?
| Renal Insufficiency, Chronic | 2 | 2020 | 564 | 0.490 |
Why?
| Tissue Plasminogen Activator | 1 | 2017 | 220 | 0.490 |
Why?
| Drug Eruptions | 1 | 2015 | 26 | 0.490 |
Why?
| Psoriasis | 3 | 2012 | 91 | 0.470 |
Why?
| Fibrinolytic Agents | 1 | 2017 | 249 | 0.470 |
Why?
| Databases, Factual | 8 | 2016 | 1268 | 0.460 |
Why?
| Hypoglycemic Agents | 2 | 2015 | 1214 | 0.460 |
Why?
| Comparative Effectiveness Research | 2 | 2012 | 151 | 0.460 |
Why?
| Diphosphonates | 2 | 2012 | 58 | 0.460 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 343 | 0.450 |
Why?
| Delivery of Health Care | 2 | 2019 | 892 | 0.450 |
Why?
| Physicians, Primary Care | 1 | 2017 | 227 | 0.450 |
Why?
| Brain Ischemia | 1 | 2017 | 304 | 0.440 |
Why?
| Anemia | 1 | 2015 | 156 | 0.440 |
Why?
| Imidazoles | 2 | 2012 | 228 | 0.430 |
Why?
| Liver Neoplasms | 2 | 2015 | 640 | 0.430 |
Why?
| Dextroamphetamine | 1 | 2012 | 3 | 0.400 |
Why?
| Antiviral Agents | 2 | 2015 | 704 | 0.400 |
Why?
| Methylphenidate | 1 | 2012 | 37 | 0.390 |
Why?
| Drug Delivery Systems | 1 | 2015 | 326 | 0.380 |
Why?
| Drug Costs | 6 | 2015 | 103 | 0.380 |
Why?
| Aged, 80 and over | 11 | 2020 | 7040 | 0.380 |
Why?
| Referral and Consultation | 1 | 2017 | 727 | 0.370 |
Why?
| Schizophrenia | 2 | 2006 | 429 | 0.370 |
Why?
| Pulmonary Embolism | 1 | 2014 | 208 | 0.370 |
Why?
| Neoplasm Metastasis | 6 | 2016 | 608 | 0.370 |
Why?
| Fumarates | 1 | 2011 | 10 | 0.360 |
Why?
| Drugs, Generic | 1 | 2011 | 17 | 0.360 |
Why?
| Hypertension | 4 | 2018 | 1238 | 0.360 |
Why?
| Drug Substitution | 1 | 2011 | 52 | 0.360 |
Why?
| Central Nervous System Stimulants | 1 | 2012 | 156 | 0.350 |
Why?
| Bone Diseases | 1 | 2011 | 61 | 0.350 |
Why?
| Postmenopause | 4 | 2016 | 370 | 0.350 |
Why?
| Stroke | 2 | 2017 | 1064 | 0.340 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2011 | 90 | 0.340 |
Why?
| Amides | 1 | 2011 | 91 | 0.340 |
Why?
| Venous Thromboembolism | 1 | 2014 | 274 | 0.340 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 201 | 0.330 |
Why?
| Multiple Myeloma | 1 | 2011 | 123 | 0.330 |
Why?
| Crohn Disease | 5 | 2012 | 211 | 0.330 |
Why?
| Arthritis, Rheumatoid | 2 | 2016 | 1108 | 0.330 |
Why?
| Diabetes Mellitus | 1 | 2018 | 1001 | 0.320 |
Why?
| Anticoagulants | 1 | 2014 | 613 | 0.320 |
Why?
| Insurance, Health | 3 | 2011 | 271 | 0.320 |
Why?
| Sick Leave | 2 | 2007 | 14 | 0.320 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2015 | 2430 | 0.320 |
Why?
| Hyperuricemia | 1 | 2009 | 45 | 0.320 |
Why?
| Antibodies, Monoclonal | 6 | 2011 | 1355 | 0.310 |
Why?
| Disease-Free Survival | 5 | 2016 | 656 | 0.310 |
Why?
| Antineoplastic Agents, Hormonal | 3 | 2016 | 158 | 0.300 |
Why?
| Costs and Cost Analysis | 7 | 2019 | 208 | 0.300 |
Why?
| Heart Failure | 2 | 2020 | 2150 | 0.300 |
Why?
| Risk Factors | 12 | 2017 | 9727 | 0.300 |
Why?
| Patient Acceptance of Health Care | 7 | 2021 | 764 | 0.290 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 398 | 0.290 |
Why?
| Absenteeism | 2 | 2005 | 49 | 0.290 |
Why?
| Quality of Life | 8 | 2021 | 2680 | 0.290 |
Why?
| Uric Acid | 1 | 2009 | 161 | 0.290 |
Why?
| Comorbidity | 8 | 2014 | 1540 | 0.290 |
Why?
| Insurance Claim Reporting | 2 | 2007 | 23 | 0.280 |
Why?
| Neoplasm Recurrence, Local | 2 | 2015 | 957 | 0.280 |
Why?
| Physicians | 1 | 2015 | 860 | 0.270 |
Why?
| Hypoglycemia | 1 | 2012 | 426 | 0.270 |
Why?
| Insulin | 2 | 2015 | 2318 | 0.270 |
Why?
| Head and Neck Neoplasms | 1 | 2012 | 534 | 0.270 |
Why?
| Health Status Indicators | 1 | 2007 | 168 | 0.260 |
Why?
| Triazoles | 3 | 2016 | 151 | 0.260 |
Why?
| Pentosan Sulfuric Polyester | 1 | 2006 | 1 | 0.260 |
Why?
| Economics, Pharmaceutical | 1 | 2006 | 10 | 0.260 |
Why?
| Cystitis, Interstitial | 1 | 2006 | 16 | 0.260 |
Why?
| Drug Resistance, Fungal | 2 | 2017 | 9 | 0.250 |
Why?
| Young Adult | 12 | 2020 | 12320 | 0.250 |
Why?
| Endometriosis | 2 | 2017 | 48 | 0.250 |
Why?
| Urinary Incontinence | 1 | 2005 | 63 | 0.230 |
Why?
| Immunoglobulin G | 1 | 2008 | 837 | 0.230 |
Why?
| Prostatic Neoplasms | 2 | 2012 | 1010 | 0.230 |
Why?
| Recurrence | 3 | 2020 | 1001 | 0.220 |
Why?
| Treatment Outcome | 12 | 2017 | 10163 | 0.210 |
Why?
| Psychotic Disorders | 1 | 2005 | 153 | 0.210 |
Why?
| Drug Therapy, Combination | 4 | 2015 | 1009 | 0.210 |
Why?
| Antibodies, Monoclonal, Humanized | 7 | 2012 | 759 | 0.200 |
Why?
| Population Surveillance | 1 | 2005 | 427 | 0.200 |
Why?
| Anti-Inflammatory Agents | 3 | 2011 | 469 | 0.190 |
Why?
| Giant Cell Tumor of Tendon Sheath | 1 | 2021 | 5 | 0.190 |
Why?
| Bone Density Conservation Agents | 2 | 2012 | 73 | 0.190 |
Why?
| Gout Suppressants | 2 | 2012 | 20 | 0.180 |
Why?
| Gastritis | 1 | 2022 | 97 | 0.180 |
Why?
| Biological Products | 2 | 2016 | 200 | 0.180 |
Why?
| Enteritis | 1 | 2022 | 94 | 0.180 |
Why?
| Hemophilia B | 1 | 2021 | 43 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2009 | 1190 | 0.180 |
Why?
| Adolescent | 17 | 2017 | 20213 | 0.180 |
Why?
| Hemophilia A | 1 | 2021 | 75 | 0.170 |
Why?
| Adenocarcinoma | 1 | 2007 | 888 | 0.170 |
Why?
| Voriconazole | 2 | 2016 | 19 | 0.170 |
Why?
| National Health Programs | 1 | 2019 | 18 | 0.170 |
Why?
| Technology Assessment, Biomedical | 1 | 2019 | 29 | 0.170 |
Why?
| Eosinophilia | 1 | 2022 | 205 | 0.170 |
Why?
| Regression Analysis | 4 | 2012 | 983 | 0.160 |
Why?
| Genetic Therapy | 1 | 2021 | 293 | 0.160 |
Why?
| Myelodysplastic Syndromes | 1 | 2021 | 129 | 0.160 |
Why?
| Microbial Sensitivity Tests | 2 | 2017 | 335 | 0.150 |
Why?
| Aging | 1 | 2009 | 1770 | 0.150 |
Why?
| Nitriles | 2 | 2016 | 160 | 0.150 |
Why?
| Treatment Failure | 2 | 2017 | 342 | 0.150 |
Why?
| Idiopathic Pulmonary Fibrosis | 2 | 2015 | 628 | 0.150 |
Why?
| Vital Capacity | 2 | 2015 | 289 | 0.150 |
Why?
| Polystyrenes | 1 | 2018 | 38 | 0.150 |
Why?
| Overweight | 1 | 2022 | 525 | 0.140 |
Why?
| 4-Aminopyridine | 1 | 2017 | 23 | 0.140 |
Why?
| Potassium | 1 | 2018 | 138 | 0.140 |
Why?
| Emergency Service, Hospital | 3 | 2014 | 1968 | 0.140 |
Why?
| Retreatment | 1 | 2017 | 70 | 0.140 |
Why?
| Aspergillosis | 1 | 2016 | 21 | 0.140 |
Why?
| Mental Disorders | 1 | 2005 | 1007 | 0.130 |
Why?
| Antihypertensive Agents | 2 | 2011 | 486 | 0.130 |
Why?
| Administration, Intravenous | 1 | 2017 | 137 | 0.130 |
Why?
| Abiraterone Acetate | 1 | 2016 | 14 | 0.130 |
Why?
| Consumer Behavior | 1 | 2017 | 68 | 0.130 |
Why?
| Patient Compliance | 2 | 2011 | 562 | 0.130 |
Why?
| Hysterectomy | 1 | 2017 | 119 | 0.130 |
Why?
| Administrative Claims, Healthcare | 1 | 2016 | 27 | 0.130 |
Why?
| Aromatase Inhibitors | 1 | 2016 | 52 | 0.130 |
Why?
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 45 | 0.130 |
Why?
| Chronic Disease | 3 | 2014 | 1701 | 0.130 |
Why?
| Capecitabine | 1 | 2016 | 47 | 0.130 |
Why?
| Health Care Rationing | 1 | 2016 | 58 | 0.130 |
Why?
| Ambulatory Care | 3 | 2015 | 506 | 0.120 |
Why?
| Clinical Protocols | 1 | 2017 | 253 | 0.120 |
Why?
| Patient Admission | 1 | 2017 | 184 | 0.120 |
Why?
| Time-to-Treatment | 1 | 2017 | 180 | 0.120 |
Why?
| Prednisone | 1 | 2016 | 236 | 0.120 |
Why?
| Disability Evaluation | 1 | 2017 | 289 | 0.120 |
Why?
| Ki-1 Antigen | 1 | 2015 | 5 | 0.120 |
Why?
| International Classification of Diseases | 1 | 2016 | 124 | 0.120 |
Why?
| Androstadienes | 1 | 2015 | 107 | 0.120 |
Why?
| Logistic Models | 2 | 2014 | 1975 | 0.120 |
Why?
| Waiting Lists | 1 | 2017 | 238 | 0.120 |
Why?
| Lymphoma, Large-Cell, Anaplastic | 1 | 2015 | 20 | 0.120 |
Why?
| Drug Interactions | 1 | 2016 | 360 | 0.120 |
Why?
| Ribavirin | 1 | 2015 | 92 | 0.120 |
Why?
| California | 2 | 2006 | 400 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2019 | 5040 | 0.110 |
Why?
| Drug Administration Schedule | 3 | 2011 | 757 | 0.110 |
Why?
| International Normalized Ratio | 1 | 2014 | 47 | 0.110 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2014 | 29 | 0.110 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2021 | 591 | 0.110 |
Why?
| Amphotericin B | 1 | 2014 | 29 | 0.110 |
Why?
| Recombinant Proteins | 1 | 2017 | 1284 | 0.110 |
Why?
| Follow-Up Studies | 5 | 2015 | 4898 | 0.110 |
Why?
| Insurance, Health, Reimbursement | 1 | 2014 | 96 | 0.110 |
Why?
| Immunoconjugates | 1 | 2015 | 101 | 0.110 |
Why?
| Drug Prescriptions | 1 | 2015 | 250 | 0.110 |
Why?
| Constipation | 1 | 2014 | 89 | 0.110 |
Why?
| Pulmonary Disease, Chronic Obstructive | 2 | 2011 | 950 | 0.110 |
Why?
| China | 1 | 2014 | 191 | 0.110 |
Why?
| Mycoses | 1 | 2014 | 70 | 0.110 |
Why?
| Models, Theoretical | 1 | 2017 | 546 | 0.110 |
Why?
| Morpholines | 1 | 2014 | 125 | 0.110 |
Why?
| ErbB Receptors | 2 | 2016 | 601 | 0.110 |
Why?
| Thiophenes | 1 | 2014 | 119 | 0.110 |
Why?
| Recovery of Function | 1 | 2017 | 643 | 0.100 |
Why?
| Pyridines | 1 | 2016 | 469 | 0.100 |
Why?
| Hodgkin Disease | 1 | 2015 | 134 | 0.100 |
Why?
| Budgets | 1 | 2012 | 14 | 0.100 |
Why?
| Warfarin | 1 | 2014 | 147 | 0.100 |
Why?
| Drug Combinations | 2 | 2011 | 323 | 0.100 |
Why?
| Allopurinol | 1 | 2012 | 61 | 0.100 |
Why?
| Multivariate Analysis | 4 | 2015 | 1494 | 0.100 |
Why?
| Adalimumab | 5 | 2011 | 44 | 0.100 |
Why?
| Laparoscopy | 1 | 2017 | 454 | 0.100 |
Why?
| Gastrointestinal Diseases | 1 | 2014 | 197 | 0.100 |
Why?
| Health Status | 2 | 2008 | 751 | 0.100 |
Why?
| Lisdexamfetamine Dimesylate | 1 | 2012 | 9 | 0.100 |
Why?
| Databases as Topic | 2 | 2009 | 62 | 0.100 |
Why?
| Immunocompromised Host | 1 | 2014 | 195 | 0.100 |
Why?
| Neoplasm Staging | 1 | 2015 | 1288 | 0.100 |
Why?
| Estradiol | 1 | 2015 | 497 | 0.100 |
Why?
| Multiple Sclerosis | 1 | 2017 | 434 | 0.090 |
Why?
| Patient Readmission | 1 | 2017 | 664 | 0.090 |
Why?
| Rivaroxaban | 1 | 2014 | 254 | 0.090 |
Why?
| Sulfonylurea Compounds | 1 | 2012 | 47 | 0.090 |
Why?
| Medicaid | 2 | 2006 | 437 | 0.090 |
Why?
| Sirolimus | 1 | 2012 | 189 | 0.090 |
Why?
| Fractures, Spontaneous | 1 | 2011 | 13 | 0.090 |
Why?
| Spinal Cord Compression | 1 | 2011 | 19 | 0.090 |
Why?
| Hypercalcemia | 1 | 2011 | 19 | 0.090 |
Why?
| Models, Statistical | 2 | 2012 | 625 | 0.090 |
Why?
| Cost Sharing | 1 | 2011 | 15 | 0.090 |
Why?
| Communication | 1 | 2017 | 838 | 0.090 |
Why?
| Efficiency | 2 | 2011 | 95 | 0.090 |
Why?
| Japan | 2 | 2021 | 98 | 0.090 |
Why?
| Bone Diseases, Metabolic | 1 | 2011 | 60 | 0.090 |
Why?
| Antidepressive Agents, Second-Generation | 1 | 2010 | 43 | 0.090 |
Why?
| Bone Neoplasms | 1 | 2012 | 229 | 0.090 |
Why?
| Bronchodilator Agents | 1 | 2011 | 245 | 0.080 |
Why?
| Severity of Illness Index | 4 | 2012 | 2736 | 0.080 |
Why?
| Angiogenesis Inhibitors | 1 | 2011 | 216 | 0.080 |
Why?
| Administration, Oral | 1 | 2012 | 757 | 0.080 |
Why?
| Linear Models | 1 | 2012 | 816 | 0.080 |
Why?
| Gastrointestinal Agents | 1 | 2009 | 60 | 0.080 |
Why?
| Surveys and Questionnaires | 3 | 2021 | 5346 | 0.080 |
Why?
| Antidepressive Agents | 1 | 2011 | 221 | 0.080 |
Why?
| Obesity | 1 | 2022 | 2860 | 0.080 |
Why?
| Etanercept | 1 | 2008 | 58 | 0.080 |
Why?
| Case-Control Studies | 2 | 2014 | 3326 | 0.080 |
Why?
| Blood Chemical Analysis | 1 | 2009 | 96 | 0.080 |
Why?
| Time Factors | 2 | 2017 | 6503 | 0.080 |
Why?
| Age Distribution | 3 | 2015 | 376 | 0.070 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 162 | 0.070 |
Why?
| Employment | 2 | 2007 | 167 | 0.070 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 998 | 0.070 |
Why?
| Digestive System Surgical Procedures | 1 | 2008 | 98 | 0.070 |
Why?
| Quality-Adjusted Life Years | 2 | 2022 | 108 | 0.070 |
Why?
| Veterans Disability Claims | 1 | 2006 | 1 | 0.070 |
Why?
| Private Sector | 1 | 2006 | 51 | 0.070 |
Why?
| Health Benefit Plans, Employee | 1 | 2006 | 23 | 0.070 |
Why?
| Ischemic Attack, Transient | 1 | 2006 | 60 | 0.060 |
Why?
| Child | 4 | 2020 | 20721 | 0.060 |
Why?
| Employer Health Costs | 1 | 2005 | 4 | 0.060 |
Why?
| Coronary Disease | 1 | 2008 | 384 | 0.060 |
Why?
| Metabolic Diseases | 1 | 2007 | 106 | 0.060 |
Why?
| Hallucinations | 1 | 2005 | 30 | 0.060 |
Why?
| Cohort Studies | 2 | 2012 | 5369 | 0.060 |
Why?
| Area Under Curve | 1 | 2005 | 281 | 0.060 |
Why?
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 236 | 0.060 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1044 | 0.060 |
Why?
| Metabolic Syndrome | 1 | 2007 | 340 | 0.060 |
Why?
| Adrenal Cortex Hormones | 1 | 2007 | 518 | 0.050 |
Why?
| Colorectal Neoplasms | 1 | 2011 | 753 | 0.050 |
Why?
| Age Factors | 2 | 2015 | 3117 | 0.050 |
Why?
| Data Collection | 1 | 2006 | 649 | 0.050 |
Why?
| Asthma | 2 | 2007 | 2215 | 0.050 |
Why?
| Psychiatric Status Rating Scales | 1 | 2005 | 523 | 0.050 |
Why?
| Lung | 1 | 2015 | 3741 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 1 | 2007 | 749 | 0.050 |
Why?
| Anti-Asthmatic Agents | 1 | 2006 | 372 | 0.050 |
Why?
| Health Policy | 1 | 2005 | 353 | 0.050 |
Why?
| Interviews as Topic | 1 | 2005 | 705 | 0.050 |
Why?
| Glucagon-Like Peptides | 1 | 2022 | 51 | 0.050 |
Why?
| Mental Health Services | 1 | 2005 | 399 | 0.040 |
Why?
| Double-Blind Method | 3 | 2011 | 1860 | 0.040 |
Why?
| Asia | 1 | 2019 | 58 | 0.040 |
Why?
| Incidence | 1 | 2006 | 2619 | 0.040 |
Why?
| Administration, Inhalation | 2 | 2011 | 664 | 0.040 |
Why?
| Disease Progression | 2 | 2015 | 2603 | 0.040 |
Why?
| Potassium Channel Blockers | 1 | 2017 | 35 | 0.040 |
Why?
| Disease Management | 2 | 2015 | 588 | 0.030 |
Why?
| Models, Econometric | 1 | 2016 | 34 | 0.030 |
Why?
| Itraconazole | 1 | 2016 | 7 | 0.030 |
Why?
| Delayed-Action Preparations | 1 | 2017 | 176 | 0.030 |
Why?
| B-Lymphocytes | 1 | 2020 | 820 | 0.030 |
Why?
| Utilization Review | 1 | 2014 | 37 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2007 | 2018 | 0.030 |
Why?
| Early Diagnosis | 1 | 2015 | 236 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 2009 | 1943 | 0.030 |
Why?
| Aspergillus | 1 | 2014 | 16 | 0.030 |
Why?
| Hypothyroidism | 1 | 2014 | 71 | 0.030 |
Why?
| Cryptococcus | 1 | 2014 | 8 | 0.030 |
Why?
| Forced Expiratory Volume | 1 | 2015 | 509 | 0.030 |
Why?
| Anemia, Iron-Deficiency | 1 | 2014 | 57 | 0.030 |
Why?
| Peripheral Vascular Diseases | 1 | 2014 | 104 | 0.030 |
Why?
| Mood Disorders | 1 | 2014 | 118 | 0.030 |
Why?
| Acute Disease | 1 | 2015 | 968 | 0.030 |
Why?
| Biopsy | 1 | 2015 | 1085 | 0.020 |
Why?
| Risk | 1 | 2014 | 852 | 0.020 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 387 | 0.020 |
Why?
| Nervous System Diseases | 1 | 2014 | 251 | 0.020 |
Why?
| Matched-Pair Analysis | 1 | 2011 | 43 | 0.020 |
Why?
| Cetuximab | 1 | 2011 | 94 | 0.020 |
Why?
| Critical Care | 1 | 2015 | 544 | 0.020 |
Why?
| Bevacizumab | 1 | 2011 | 131 | 0.020 |
Why?
| Tablets | 1 | 2010 | 37 | 0.020 |
Why?
| Length of Stay | 1 | 2015 | 1121 | 0.020 |
Why?
| State Medicine | 1 | 2009 | 20 | 0.020 |
Why?
| Epidemiologic Methods | 1 | 2009 | 74 | 0.020 |
Why?
| United Kingdom | 1 | 2009 | 256 | 0.020 |
Why?
| Sex Factors | 1 | 2015 | 1949 | 0.020 |
Why?
| Remission Induction | 1 | 2009 | 269 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 2009 | 145 | 0.020 |
Why?
| Insurance Coverage | 1 | 2010 | 222 | 0.020 |
Why?
| Maximum Tolerated Dose | 1 | 2009 | 193 | 0.020 |
Why?
| Odds Ratio | 1 | 2011 | 1022 | 0.020 |
Why?
| Europe | 1 | 2009 | 362 | 0.020 |
Why?
| Probability | 1 | 2009 | 308 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2009 | 423 | 0.020 |
Why?
| Canada | 1 | 2009 | 345 | 0.020 |
Why?
| Confidence Intervals | 1 | 2008 | 318 | 0.020 |
Why?
| Reference Values | 1 | 2009 | 780 | 0.020 |
Why?
| Sex Distribution | 1 | 2008 | 359 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2014 | 2697 | 0.020 |
Why?
| Prognosis | 1 | 2015 | 3780 | 0.020 |
Why?
| Models, Biological | 1 | 2014 | 1693 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2012 | 1358 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2015 | 2521 | 0.020 |
Why?
| Health Status Disparities | 1 | 2008 | 248 | 0.020 |
Why?
| Infant | 2 | 2007 | 8913 | 0.010 |
Why?
| Child, Preschool | 2 | 2007 | 10373 | 0.010 |
Why?
| Emergency Medical Services | 1 | 2007 | 548 | 0.010 |
Why?
| Risk Assessment | 1 | 2009 | 3256 | 0.010 |
Why?
| Body Mass Index | 1 | 2007 | 2262 | 0.010 |
Why?
| Infant, Newborn | 1 | 2006 | 5687 | 0.010 |
Why?
|
|
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|